Interpace Biosciences, Inc. (MUN:PF42)

Market Cap	33.71M +905.7%
Revenue (ttm)	31.64M -20.5%
Net Income	21.40M +435.6%
EPS	0.78 +24.1%
Shares Out	n/a
PE Ratio	1.58
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	1.280
Previous Close	1.280
Day's Range	1.280 - 1.280
52-Week Range	1.070 - 1.720
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 12, 2026

About Interpace Biosciences

Interpace Biosciences, Inc. provides molecular diagnostic tests and pathology services for evaluating cancer risk in the United States. It offers ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. The company also provides ThyraMIR v2, which assesses thyroid nodules for malignancy risk using a proprietary microRNA gene expression classifier. It primarily serves physicians, cancer centers, clinics, laboratories, pathology groups, and hospitals. The company was formerly known as Interpace Diagnostics Group, Inc. and cha...

• Industry: Medical Laboratories
• Founded: 1986
• Employees: 102
• Stock Exchange: Munich Stock Exchange
• Ticker Symbol: PF42

Financial Performance

In 2025, Interpace Biosciences's revenue was $38.73 million, a decrease of -17.47% compared to the previous year's $46.93 million. Earnings were $24.58 million, an increase of 293.96%.

Financial numbers in USD

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Aug 26, 2026

Data Sources Report a data error